|
|
 | |||
|
|
|
|
| |||
This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the author's clinical recommendations.
A 28-year-old woman is referred for advice about the management of recently diagnosed chronic myelogenous leukemia (CML). She was in excellent overall health but was incidentally found to have an elevated white-cell count of 31,000 per cubic millimeter. Bone
The Clinical Problem
Pathophysiology and Effect of Therapy
Clinical Evidence
Clinical Use
Adverse Effects
Areas of Uncertainty
Guidelines
Recommendations
Source Information
From the Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit.
Address reprint requests to Dr. Schiffer at the Division of Hematology/Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, HWCRB 4th Fl., 4100 John R, Detroit, MI 48201, or at schiffer@karmanos.org.
Related Letters:
Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
Defuentes G., Bladé J.-S., Berets O., Quintás-Cardama A., Kantarjian H., Cortes J., Schiffer C. A.
Extract |
Full Text |
PDF
N Engl J Med 2007;
357:1556-1558, Oct 11, 2007.
Correspondence
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved. |
Previous
